

In This Issue

- FDA/CDC Warn Against Use of Ivermectin to Prevent and Treat COVID-19
- Call for Immediate End to Prescribing, Dispensing, and Use of Ivermectin
- Highmark Increases 2022 Marketplace Premiums
- MSD Hot Topic CME Event - Performance in Late Career Physicians
- Practice Management and Education Session – HIPAA Rules: Are You Compliant?
- Buprenorphine 101 Class: Prescribing And Referring
- CDC FAQs to Help Parents as School Resumes for Their Children
- University of Delaware Business Programs
- MSD Holiday Closing

Reminders

MEDICAL FRONT OFFICE SKILLS CERTIFICATE PROGRAM

October 21-22, 9:00 am – 5:00 pm at the MSD Conference Center in Newark

To register visit <https://reg.planetreg.com/MFOS2021>.

2021 HIPAA/OSHA/BLS TRAINING

Get your 2021 HIPAA, mandatory OSHA, & BLS training scheduled with MSD Compliance Coordinator Dwayne Downs at 302-366-1023.

Contact MSD

302-366-1400
MedicalSocietyofDelaware.org
To unsubscribe contact
Kristie Stewart at
302-224-5196
Kristie.Stewart@medsocdel.org

Copyright 2021. All rights reserved.

FDA/CDC Warn Against Use of Ivermectin to Prevent and Treat COVID-19

The Centers for Disease Control and Prevention (CDC) has issued a health alert warning physicians and the public about the rise in prescriptions for the anti-parasitic drug Ivermectin for use in the treatment or prevention of COVID-19. The CDC also cautioned about the risk of severe illness caused by Ivermectin, which was seen in increased calls to poison centers. Current NIH Treatment Guidelines state that there is insufficient evidence to recommend either for or against the use of Ivermectin for the treatment of COVID-19 outside of clinical trials. Additionally, there is no evidence to suggest that Ivermectin can prevent you becoming infected with COVID-19. Visit <https://tinyurl.com/dhd4bc62>.

Call for Immediate End to Prescribing, Dispensing, and Use of Ivermectin

The American Medical Association and other health care organizations issued a joint statement calling for an immediate end to the ordering, prescribing or dispensing of Ivermectin for prevention or treatment of COVID-19. To read the joint statement visit <https://tinyurl.com/uhe63wa>.

Highmark Increases 2022 Marketplace Premiums

Highmark Blue Cross Blue Shield of Delaware, which offers the state's Affordable Care Act (ACA) health plans, will increase base rates an average of 3% for the 2022 plan year. The rate change does not apply to Medicare, Medicaid, or those with group or individual policies outside the Marketplace. The announcement comes after extensive, in-depth independent actuarial reviews and a public comment period on the insurer's initial proposal of a 4% increase. Visit <https://tinyurl.com/yfa4rshy>.

MSD Hot Topic CME Event - Performance in Late Career Physicians

The Medical Society of Delaware presents the next Hot Topic CME on Thursday, September 23, 2021 6:00 pm - 7:00 pm. This virtual presentation is intended for physicians and will discuss physician aging and competency, as well as review of history, rationale, and implementation of age-based physician assessment programs. This activity has been approved for a maximum of 1 AMA PRA Category 1 Credit™. To register visit <https://reg.planetreg.com/HotTopicLateCareerPhysicians>.

Practice Management and Education Session - HIPAA Rules: Are You Compliant?

Please join us for the next Practice Management and Education Session, presented by Dwayne Downs, MSD's Training & Compliance Coordinator. This session will provide an overview of HIPAA policy and procedures, how to implement a HIPAA plan and much more. The virtual event will be held on **Thursday, September 30th from 12:00 – 1:00 pm**. To register please visit <https://reg.planetreg.com/HIPAA>.

Buprenorphine 101 Class: Prescribing And Referring

Recent federal changes no longer require providers to go through the traditional 8-hour training to obtain their X waiver for prescribing limited amounts of buprenorphine. The 2-hour class is available for providers to learn from subject matter experts about the basics of incorporating Medication for Opioid Use Disorder (MOUD) into their treatment plans for patients with opioid use disorder. The virtual session is scheduled for **Tuesday, September 14 from 5:00-7:00 p.m.** Instruction will be provided on how to apply for an X waiver through SAMHSA. Training is open to all Delaware physicians, residents, medical students, and advance practice providers. Those applying for their X waiver at the end of the course will receive \$750 in compensation, as well as 2.0 CME credits for full participation. For more information visit <https://tinyurl.com/2y5xvz2b>.

CDC FAQs to Help Parents as School Resumes for Their Children

Children are going to hospitals at an increased rate due to rising COVID-19 transmission from the Delta variant, especially in communities with low vaccination rates. The Delaware Department of Health and Social Services and Division of Public Health wants to share with you **NEW** resources (<https://tinyurl.com/u6eu7zez>) for parents as in-person schooling resumes this fall.

University of Delaware Business Programs

MSD partnered with the University of Delaware to offer you flexible and affordable degree options through a fully online classroom that was designed for working adults. **Education Benefits for Medical Society of Delaware Members include:** A 10% Tuition Reduction, Free Transfer Evaluation, 100% online programs offer flexibility and convenience. For more information visit <https://tinyurl.com/5ha8944w>.

MSD Holiday Closing

In observance of the Labor Day Holiday, MSD will be closed on Monday, September 6, 2021.